Gynae-Oncology Research

The Gynae-Oncology Department provide care for women with all types and stages of gynaecological cancers. The studies we undertake explore a variety of research directions. These include collecting information regarding registries, tissue collection for biobank and translational research, exploring different clinical, surgical and oncology treatments, effects of conventional and non-conventional pain management, investigating the effects of exercise during chemotherapy and end of life care. We aim to continuously expand our understanding of gynaecological cancers with the research we conduct.

Our Research Team

Associate Professor Rhonda Farrell	Director of Gynae-Oncology
Associate Professor Selvan Pather	Senior Staff Specialist Gynae-Oncology
Associate Professor Trevor Tedaja-Berges	Senior Staff Specialist Gynae-Oncology
Associate Professor Samir Saidi	Senior Staff Specialist Gynae-Oncology
Dr Robyn Sayer	Senior Staff Specialist Gynae-Oncology
Dr Michelle Harrison	Senior Staff Specialist Medical Oncology
Dr Tahlia Scheinberg	Senior Staff Specialist Medical Oncology
Dr Sita Murugappan	Fellow
Dr Marta Preston	Fellow
Dr Jonathan Sandeford	Fellow
Dr Marilyn Boo	Fellow
Dr Magdalen Dunn	Resident Medical Officer
Dr Laura Sunderland	Research Masters Student
Dr Sadaf Kalam	Senior Clinical Trials Manager
Shannon Philp	Nurse Practitioner
Belinda Zielony	Clinical Nurse Consultant
Angelica Lim	Clinical Nurse Specialist
Pranita Kadlag	Data Manager
Katherin Murillo Acosta	Patient Navigator
Kathy Roorda	Patient Navigator
Carla Loteria	Patient Navigator
Bianca Dimitrovska	Patient Navigator

Selected Grants

Amount awarded	Grant and project details
$3,158,864	NHMRC, 2024-2028 Endo-3, phase III randomised trial comparing sentinel node biopsy with no node dissection in early-stage endometrial cancer. RPA Investigator: Farrell R
$100,000	Gynae-Oncology Research Advisory Group (GORAG) Research Grants, 2024-2026 Addressing nutrition issues in ovarian cancer patients undergoing cytoreductive surgery: a novel co-design approach. Investigators: Cherry K, Farrell R.
$20,000	SurFebruary Cancer Research Fund, 2024-2025 Barriers to surgery in ovarian cancer: an Australian retrospective review. Investigators: Sunderland L, Farrell R.
$10,000	RANZCOG NSW State Committee Fellow Research Grant, 2024-2025 Comparing patient and their clinician's perceptions of recovery in the Enhanced recovery after surgery (ERAS) Program following major gynaecological oncology surgery- a quality improvement project. Investigator: Boo M.
$544,050	NHMRC Ideas Grant, 2023-2025 Discovery of eosinophil-derived thermogenic beiging factors to combat obesity. RPA Investigator: Farrell R.
$40,000	Chris O'Brien Lifehouse Research Grant, 2022-2025 Diagnostic performance of diffusion-weighted MRI compared to laparoscopy in predicting feasibility of complete cytoreduction in advanced ovarian, fallopian tube and primary peritoneal cancer. Investigators: Farrell R, McGauran M, YuXuan Y, Lam K, McNally O, Shadbolt C, Kouloyan-Ilic S.
$3,520,935	NHMRC, 2020-2025 Measuring adherence to best practice guidelines for the management of ovarian cancer in Australia to determine the extent to which variation in care influences clinical and patient-reported. RPA Investigator: Farrell R.
$686,674	MRFF, 2020-2025 HyNOVA- A randomised study comparing hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer. RPA Investigator: Farrell R.

Our Publications

2024

Coates HW, Nguyen TB, Du X, Olzomer EM, Farrell R, Byrne FL, Yang H, Brown AJ. The constitutively active form of a key cholesterol synthesis enzyme is lipid droplet-localized and upregulated in endometrial cancer tissues. J Biol Chem. 2024 May;300(5):107232. doi: 10.1016/j.jbc.2024.107232. Epub 2024 Mar 26.

Farrell R, Zaunders J, Poynten IM, Anderson L, Evans L. Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia. Gynecol Oncol Rep. 2024 Feb 23;52:101350. doi: 10.1016/j.gore.2024.101350.

Langston-Cox A, Warton E, Tipping N, Odgers HL, Nightingale A, Goni S, Thorn J, Brown K, Unger HW. Aeromedical retrieval for suspected preterm labour or rupture of membranes in the Northern Territory, Australia: may some cases be safely not retrieved? BMC Pregnancy Childbirth. 2024 Nov 30;24(1):804. doi: 10.1186/s12884-024-07013-w.

Li T, Timmins HC, Mahfouz FM, Trinh T, Mizrahi D, Horvath LG, Harrison M, Grimison P, Friedlander M, Marx G, Boyle F, Wyld D, Henderson R, King T, Baron-Hay S, Kiernan MC, Rutherford C, Goldstein D, Park SB. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy. JAMA Netw Open. 2024 Aug 1;7(8):e2424139. doi: 10.1001/jamanetworkopen.2024.24139.

Mellor R, Ardolino L, Scheinberg T, Fitzpatrick M, Lin HM, Bonnitcha P, Sullivan D, Meikle PJ, Stockler MR, Moujaber T, Joshua A, Horvath L. Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy. Ther Adv Med Oncol. 2024 Dec 16;16:17588359241307814. doi: 10.1177/17588359241307814.

Morton R, Webb PM, Na R, Obermair A, Farrell R. Mismatch repair status and surgical approach in apparent early-stage endometrial cancer. Int J Gynecol Cancer. 2024 Apr 1;34(4):535-543. doi: 10.1136/ijgc-2023-005234.

Nash R, Saidi S. Outpatient hysteroscopy: Suitable for all? A retrospective cohort study of safety, success and acceptability in Australia. Aust N Z J Obstet Gynaecol. 2024 Oct;64(5):475-481. doi: 10.1111/ajo.13816. Epub 2024 Apr 4.

Sandeford J, Herbst U, Lum T, Anderson L, Pather S. High-grade squamous intraepithelial lesions and adenocarcinoma in situ with a negative HPV cervical screening test. The role of HPV-ISH testing: A retrospective review. Aust N Z J Obstet Gynaecol. 2025 Apr;65(2):297-300. doi: 10.1111/ajo.13892. Epub 2024 Nov 5.

Sfeir S, Allen L, Algera MD, Morton R, Farrell R, Brennan D, Driel WJV, Rijken MJ, Eiken M, Sundar SS, Coleman RL; collaborators of the Global Equality in Ovarian Cancer Care project group. Exploring global barriers to optimal ovarian cancer care: thematic analysis. Int J Gynecol Cancer. 2024 Sep 2;34(9):1408-1415. doi: 10.1136/ijgc-2024-005449.

Vu J, Koh C, Solomon M, Brown K, Karunaratne S, Cole R, Smith P, Raichurkar P, Denehy L, Riedel B; Prehabilitation Expert Collaborative; Steffens D. Patients' and carers' views on research priorities in prehabilitation for cancer surgery. Support Care Cancer. 2024 May 24;32(6):378. doi: 10.1007/s00520-024-08585-1.

Poynten IM, Jin F, Farrell R, Tejada-Berges T, Law C, Hillman R, Roberts J, Grulich A. Anal cancer screening in women with a history of human papillomavirus-related lower genital tract cancers: a pilot study. Gynecol Obstet Clin Med. 2024;4. doi:10.1136/gocm-2024-000001.

2023

Algera MD, Morton R, Sundar SS, Farrell R, van Driel WJ, Brennan D, Rijken MJ, Sfeir S, Allen L, Eiken M, Coleman RL; collaborators of the Global Equality in Ovarian Cancer Care project group. Exploring international differences in ovarian cancer care: a survey report on global patterns of care, current practices, and barriers. Int J Gynecol Cancer. 2023 Oct 2;33(10):1612-1620. doi: 10.1136/ijgc-2023-004563.

Coates HW, Capell-Hattam IM, Olzomer EM, Du X, Farrell R, Yang H, Byrne FL, Brown AJ. Hypoxia truncates and constitutively activates the key cholesterol synthesis enzyme squalene monooxygenase. Elife. 2023 Jan 19;12:e82843. doi: 10.7554/eLife.82843.

Farrell R. The current and potential future role of peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of advanced epithelial ovarian cancer in Australia. PhD Thesis. July 2023 doi.org/10.26190/unsworks/25081

Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer. 2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582. Epub 2022 Dec 26.

Li T, Timmins HC, Trinh T, Mizrahi D, Harrison M, Horvath LG, Grimison P, Friedlander M, Kiernan MC, King MT, Rutherford C, Goldstein D, Park SB. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes. J Natl Compr Canc Netw. 2023 Feb;21(2):125-132.e3. doi: 10.6004/jnccn.2022.7074.

Mizrahi D, Goldstein D, Trinh T, Li T, Timmins HC, Harrison M, Marx GM, Hovey EJ, Lewis CR, Friedlander M, Park SB. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy. Asia Pac J Clin Oncol. 2023 Feb;19(1):243-249. doi: 10.1111/ajco.13834. Epub 2022 Jul 25.

Odgers H, Anderson L, Kok PS, Farrell R. Dedifferentiated umbilical metastases from low grade endometrioid endometrial adenocarcinoma complicated by super-obesity: A case report. Int J Surg Case Rep. 2023 Jul;108:108449. doi: 10.1016/j.ijscr.2023.108449. Epub 2023 Jul 1.

Pitiyarachchi O, Lee YC, Sim HW, Srirangan S, Mapagu C, Kirk J, Harnett PR, Balleine RL, Bowtell DDL, Samimi G, Brand AH, Marsh DJ, Beale P, Anderson L, Bouantoun N, Provan P; INOVATe Investigators; Ramus SJ, DeFazio A, Friedlander M. Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Transl Oncol. 2023 May;31:101638. doi: 10.1016/j.tranon.2023.101638. Epub 2023 Feb 18.

Raichurkar P, Denehy L, Solomon M, Koh C, Pillinger N, Hogan S, McBride K, Carey S, Bartyn J, Hirst N, Steffens D; Prehabilitation Expert Collaborative. Research Priorities in Prehabilitation for Patients Undergoing Cancer Surgery: An International Delphi Study. Ann Surg Oncol. 2023 Nov;30(12):7226-7235. doi: 10.1245/s10434-023-14192-x. Epub 2023 Aug 24.

Takenaka K, Olzomer EM, Hoehn KL, Curry-Hyde A, Jun Chen B, Farrell R, Byrne FL, Janitz M. Investigation of circular RNA transcriptome in obesity-related endometrial cancer. Gene. 2023 Mar 1;855:147125. doi: 10.1016/j.gene.2022.147125. Epub 2022 Dec 19.

2022

Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, O'Connell R, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT, GCIG Symptom Benefit Group: Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol 2022 Aug;166(2):254-262. DOI: 10.1016/j.ygyno.2022.05.024

Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K, Australian Ovarian Cancer Study OCP, Lifestyle S, the TS: TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. J Clin Oncol: JCO2102108, 2022. DOI: 10.1200/JCO.21.02108

Dokter E, Anderson L, Cho SM, Cohen-Hallaleh V, Lam KM, Saidi SA, Kitzing YX. Radiology-pathology correlation of endometrial carcinoma assessment on magnetic resonance imaging. Insights Imaging. 2022 Apr 25;13(1):80. doi: 10.1186/s13244-022-01218-3.

Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M; HyNOVA Protocol Steering Committee. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). J Gynecol Oncol. 2022 Jan;33(1):e1. doi: 10.3802/jgo.2022.33.e1. Epub 2021 Oct 18.

Farrell R, Liauw WS, Morris DL. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years' experience. BMC Surg. 2022 Sep 12;22(1):338. doi: 10.1186/s12893-022-01786-7.

Feddersen J, Carter J, Pather S, Saidi SA. Identifying risk factors for post-operative bleeding in women undergoing loop electrosurgical excision procedure for cervical dysplasia. Aust N Z J Obstet Gynaecol. 2022 Oct;62(5):740-747. doi: 10.1111/ajo.13575. Epub 2022 Jul 29.

Hill S, Anderson L, Pather S. Metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium; a case report and review of the literature. Gynecol Oncol Rep. 2022 Aug 5;43:101061. doi: 10.1016/j.gore.2022.101061.

Hodge, T., Naaman, Y. , Cade, T. , Neesham, D. , Jones, A. and McNally, O. (2022) Patterns of Recurrence in Low-Risk Endometrial Cancer. Open Journal of Obstetrics and Gynecology, 12, 1155-1165. doi: 10.4236/ojog.2022.1211100.

Hooshmand K, Goldstein D, Timmins HC, Li T, Harrison M, Friedlander ML, Lewis CR, Lees JG, Moalem-Taylor G, Guennewig B, Park SB, Kwok JB. Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. J Transl Med. 2022 Dec 6;20(1):564. doi: 10.1186/s12967-022-03754-4.

Ip E, Young AL, Scheinberg T, Harrison M, Beale P, Goodwin A. Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer. Asia Pac J Clin Oncol. 2022 Oct;18(5):e414-e419. doi: 10.1111/ajco.13741. Epub 2022 Jan 30.

Kaakoush NO, Olzomer EM, Kosasih M, Martin AR, Fargah F, Lambie N, Susic D, Hoehn KL, Farrell R, Byrne FL. Differences in the Active Endometrial Microbiota across Body Weight and Cancer in Humans and Mice. Cancers (Basel). 2022 Apr 25;14(9):2141. doi: 10.3390/cancers14092141.

Kalam SN, Dowland S, Lindsay L, Murphy CR. Porosomes in uterine epithelial cells: Ultrastructural identification and characterization during early pregnancy. J Morphol. 2022 Nov;283(11):1381-1389. doi: 10.1002/jmor.21504. Epub 2022 Oct 7.

Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, Kommoss FKF, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ, Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, Hirasawa A, Heitz F, Karlan BY, Goode EL, Sinn P, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Steed H, Le ND, Gayther SA, Lawrenson K, Pharoah PDP, Konecny G, Cook LS, Ramus SJ, Kelemen LE, Köbel M. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Arch. 2022 Apr;480(4):855-871. doi: 10.1007/s00428-021-03232-0. Epub 2021 Nov 15.

Krasovitsky M, Lee YC, Sim HW, Chawla T, Moore H, Moses D, Baker L, Mandel C, Kielar A, Hartery A, O'Malley M, Friedlander M, Oza A, Wang L, Lheureux S, Wilson M. Inter- and Intra- Observer Variability o fRECIST Assessment in Ovarian Cancer. Int J Gynecol Cancer 2022;32:656-661. DOI: 10.1136/ijgc-2021-003319

Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML, GCIG Symptom Benefit Group: Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer 2022;32:761-768. DOI: 10.1136/ijgc-2021-003142

Mahfouz FM, Park SB, Li T, Timmins HC, Horvath LG, Harrison M, Grimison P, King T, Goldstein D, Mizrahi D. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients. Clin Auton Res. 2022 Dec;32(6):497-506. doi: 10.1007/s10286-022-00895-w. Epub 2022 Sep 21.

McCarthy RL, Farrell R, Lochhead A, Anderson L. A case of mesonephric-like adenocarcioma of the ovary. Pathology 2022;54:S1:S53 doi: org/10.1016/j.pathology.2021.12.172

Meagher NS, Gorringe KL, Wakefield M, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, Mallitt KA, Doherty JA, Harris HR, Schildkraut JM, Berchuck A, Cushing-Haugen KL, Chezar K, Chou A, Tan A, Alsop J, Barlow E, Beckmann MW, Boros J, Bowtell DDL; AOCS Group; Brand AH, Brenton JD, Campbell I, Cheasley D, Cohen J, Cybulski C, Elishaev E, Erber R, Farrell R, Fischer A, Fu Z, Gilks B, Gill AJ; Australian Pancreatic Genome Initiative; Gourley C, Grube M, Harnett PR, Hartmann A, Hettiaratchi A, Høgdall CK, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kim BG, Kim JW, Kim JH, Klett K, Koziak JM, Lai T, Laslavic A, Lester J, Leung Y, Li N, Liauw W, Lim BWX, Linder A, Lubiński J, Mahale S, Mateoiu C, McInerny S, Menkiszak J, Minoo P, Mittelstadt S, Morris D, Orsulic S, Park SY, Pearce CL, Pearson JV, Pike MC, Quinn CM, Mohan GR, Rao J, Riggan MJ, Ruebner M, Salfinger S, Scott CL, Shah M, Steed H, Stewart CJR, Subramanian D, Sung S, Tang K, Timpson P, Ward RL, Wiedenhoefer R, Thorne H; kConFab Investigators; Cohen PA, Crowe P, Fasching PA, Gronwald J, Hawkins NJ, Høgdall E, Huntsman DG, James PA, Karlan BY, Kelemen LE, Kommoss S, Konecny GE, Modugno F, Park SK, Staebler A, Sundfeldt K, Wu AH, Talhouk A, Pharoah PDP, Anderson L, DeFazio A, Köbel M, Friedlander ML, Ramus SJ. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. Clin Cancer Res. 2022 Dec 15;28(24):5383-5395. doi: 10.1158/1078-0432.CCR-22-1206.

Obermair A, McNally O, Farrell R, Ribeiro R, Ng JS. Are endometrial cancer clinical practice management guidelines sufficiently consumer centric? Int J Gynecol Cancer. 2022 Jul 4;32(7):961-962. doi: 10.1136/ijgc-2022-003580.

Ooi S, Eskaroos MA, Pather S, Carter J, Saidi S. Patient expectations and experiences with loop electrosurgical excision procedure in inpatient and outpatient settings. Aust N Z J Obstet Gynaecol. 2022 Oct;62(5):720-724. doi: 10.1111/ajo.13556. Epub 2022 Jun 28.

Robson D, de Vries B, Pather S, Marren A. Fertility preservation in gynaecology oncology patients: Experience from an Australian tertiary oncology centre. Aust N Z J Obstet Gynaecol. 2022 Aug;62(4):542-547. doi: 10.1111/ajo.13498. Epub 2022 Feb 15.

Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G. Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. Int J Gynecol Cancer, 2022. DOI: 10.1136/ijgc-2021-003009.

Sykes PH, Simcock BJ, Innes CR, Harker D, Williman JA, Whitehead M, van der Griend RA, Lawton BA, Hibma M, Fitzgerald P, Dudley NM, Petrich S, Eva L, Bergzoll C, Kathuria J, McPherson G, Tristram A, Faherty J, Hardie D, Robertson A, Robertson V, Pather S, Wrede CD, Gastrell F, Fentiman G, John M, White E, Parker C, Sadler L. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. Am J Obstet Gynecol. 2022 Feb;226(2):222.e1-222.e13. doi: 10.1016/j.ajog.2021.09.009. Epub 2021 Sep 14.

Takenaka K, Curry-Hyde A, Olzomer EM, Farrell R, Byrne FL, Janitz M. Investigation of Transcriptome Patterns in Endometrial Cancers from Obese and Lean Women. Int J Mol Sci. 2022 Sep 29;23(19):11471. doi: 10.3390/ijms231911471.

Teoh J, Pather S, Narayan R. Use of an Arabin pessary to prevent preterm birth in pregnancy complicated by a short cervix after cervical conization for cervical adenocarcinoma with residual disease: A case report and literature review. Case Rep Womens Health. 2022 Aug 5;36:e00437. doi: 10.1016/j.crwh.2022.e00437.

Timmins HC, Li T, Goldstein D, Trinh T, Mizrahi D, Harrison M, Horvath LG, Friedlander M, Kiernan MC, Park SB. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. J Cancer Surviv. 2022 Apr;16(2):223-232. doi: 10.1007/s11764-021-01012-y. Epub 2021 Feb 27.

Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treatment Reviews 2022;107: 102396. DOI: 10.1016/j.ctrv.2022.102396

2021

Barry, L., Pather, S., Gargya, A. and Marren, A. (2021). Prolactin-Secreting Leiomyoma Causing Hyperprolactinaemia Unresponsive to Dopamine Agonist Therapy and Resolution following Myomectomy. Case Rep. Endocrinol. 2021.

Bhandoria, G. P., Noll, F., Hsu, H. C., Jones, S. E. F., Farrell, R. and Nair, N. (2021). Early Career Research and Publications Network: an International Gynecologic Cancer Society Initiative. Int. J. Gynecol. Cancer 31, 1398-1399.

Farrell, R. (2021). Reply to Letter to the Editor-Management of patients with advanced ovarian cancer- role of complete cytoreduction and HIPEC: Attitudes of gynaecologist oncologists in two different continents. Aust. N. Z. J. Obstet. Gynaecol. 61, E2-E3.

Farrell, R. and Burling, M. (2021). HIPEC: Turning up the heat on ovarian cancer. Aust. New Zeal. J. Obstet. Gynaecol. 61, 11-15.

Georgevsky, D., Li, Y., Pather, S., Tejada-Berges, T., Robinson, D., Laurence, J., Campbell, N., Wyburn, K., Liyanagama, K., Narayan, R., et al. (2021). Uterus transplantation and pregnancy induction: Approved protocol at the Royal Prince Alfred Hospital. Aust. New Zeal. J. Obstet. Gynaecol. 61, 621-624.

Hickey, M., Moss, K. M., Krejany, E. O., Wrede, C. D., Brand, A., Kirk, J., Symecko, H. L., Domchek, S. M., Tejada-Berges, T., Trainer, A., et al. (2021). What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol. Oncol. 163, 148-154.

Islam, R. M., Davis, S. R., Bell, R. J., Tejada-Berges, T., Wrede, C. D., Domchek, S. M., Meiser, B., Kirk, J., Krejany, E. O. and Hickey, M. (2021). A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Menopause 28, 748-755.

Mizrahi D., Goldstein D., Li T, Timmins H.C., Trinh T., Harrison M., Marx G.M, Hovey E.J, Lewis C.R., F. M. and P. S. B. (2021). Physical activity levels and predictors in cancer survivors treated with neurotoxic chemotherapy.

Mylvaganam, G., Allanson, E., Allanson, B., Philp, S., Pather, S., Farrell, R., Carter, J. and Tejada-Berges, T. (2021). Assessment of current follow-up for complete molar pregnancies: A single centre review. Aust. New Zeal. J. Obstet. Gynaecol. 61, 213-216.

Sjoquist, K. M., Espinoza, D., Mileshkin, L., Ananda, S., Shannon, C., Yip, S., Goh, J., Bowtell, D., Harrison, M. and Friedlander, M. L. (2021). REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecol. Oncol. 161, 374-381.

Timmins, H. C., Li, T., Trinh, T., Kiernan, M. C., Harrison, M., Boyle, F., Friedlander, M., Goldstein, D. and Park, S. B. (2021). Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. Oncologist 26, 366-374.

Werner, B., Yuwono, N., Duggan, J., Liu, D., David, C., Srirangan, S., Provan, P., DeFazio, A., Arora, V., Farrell, R., et al. (2021). Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecol. Oncol. 162, 720-727.

Xie, H., Morton, R., Balendran, J., Philp, S., Saidi, S., Farrell, R., Anderson, L. and Pather, S. (2021). The impact of primary human papillomavirus screening on negative loop excision histology following biopsy-proven high-grade cervical intra-epithelial lesions: A review from a large tertiary colposcopy unit. Aust. N. Z. J. Obstet. Gynaecol. 61, 941-948.

2020

Gynae-Oncology Research

Our Research Team

Selected Grants

Our Publications

2024

Gynae-Oncology Research

Gynae-Oncology Research

Our Organisation

Make a Donation

Our Hospitals

Care in our Community

Right to Information

Your feedback

Plans

Publications

Quick Links